Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

Published 2016 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Authors
Keywords
PCSK9, LDL-C, LDL-receptor, VLDL, PCSK9-Centric lipid lowering, Pleiotropic, Monoclonal antibody, CRISPR-CAS9, Anti-sense oligonucleotide, Peptide-mimetic, Adnectin, Vaccine, Lipoprotein-apheresis
Journal
ATHEROSCLEROSIS
Volume 248, Issue -, Pages 62-75
Publisher
Elsevier BV
Online
2016-03-10
DOI
10.1016/j.atherosclerosis.2016.02.018

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.